Showing 1431-1440 of 2182 results for "".
- Evolus’ Jeuveau Can Stay on U.S. Market For Nowhttps://modernaesthetics.com/news/evolus-jeuveau-gets-stay-of-execution/2473061/Evolus Inc. can remain for sale in the U.S. temporarily while an appeals court re-considers an import ban won by AbbVie Inc.’s Allergan that was slated to go into effect on Feb. 16, 2021, according to
- Revance: ePosters Showcase Data for DaxibotulinumtoxinA and RHA Line at Maui Dermhttps://modernaesthetics.com/news/revance-eposters-showcase-data-for-daxibotulinumtoxina-and-rha-line-at-maui-derm/2473053/Three ePosters presented at the Maui Derm for Dermatologists 2021 meeting feature data for DaxibotulinumtoxinA for Injection and the RHA® Collection of hyaluronic acid based dermal fillers, both from Revance Therapeutics. Revance repo
- Pulse Biosciences Receives European Clearance for CellFX Systemhttps://modernaesthetics.com/news/pulse-biosciences-receives-european-clearance-for-cellfx-system/2473050/Pulse Biosciences, Inc. will proceed with its planned controlled launch of the CellFX System to medical practices within the European Union (EU), now that it has received CE mark for the system. The European clearance is for the treatment of general dermatologic conditions, includi
- Allergan Aesthetics Enters Into Option to Acquire Cypris Medicalhttps://modernaesthetics.com/news/allergan-aesthetics-enters-into-option-to-acquire-cypris-medical/2473045/Allergan Aesthetics, an AbbVie company has entered into a warrant agreement with Cypris Medical, a privately held, medical device company based in Chicago. Following the completion of a clinical trial to be initiated in 2021, Allergan Aesthetics will have the right to exercis
- Done Deal: DermOQ Oxygen Lab Acquires ECHO2 Plus Oxygen Facial Treatment Product Line from Skin Products, Inc.https://modernaesthetics.com/news/done-deal-dermoq-oxygen-lab-acquires-echo2-plus-oxygen-facial-treatment-product-line-from-skin-products-inc/2473034/DermOQ Oxygen Lab closed their acquisition of ECHO2 Plus Oxyceuticals oxygen facial treatment product line from Skin Products, Inc. for an undisclosed amount. "ECHO2 Plus is a 45-minute facial treatment offered at physician's offices, spas, hotels and corporate custom
- Phase 2 DaxibotulinumtoxinA Data Highlight Efficacy for Upper Facial Lineshttps://modernaesthetics.com/news/phase-2-daxibotulinumtoxina-data-highlight-efficacy-for-upper-facial-lines/2473032/Topline efficacy and safety results from the phase 2 multicenter, open-label study of Revance's investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, show high levels of patient satisfaction. The 36-week study enrolled 48
- Developing Story: AbbVie’s Allergan Wins Trade Secret Case Against Evolushttps://modernaesthetics.com/news/developing-story-abbvies-allergan-wins-trade-secret-case-against-evolus/2473030/AbbVie Inc.’s Allergan won a U.S. trade agency order to block Evolus Inc. and its partner Daewoong Pharmaceutical Co. from importing Jeuveau into the U.S. for 21 months, according to media reports. The U.S. International Trade Commission upheld a judge’s findings that Jeuvea
- Call for Entries: Merz Aesthetics Announces First-Ever Innovation Forumhttps://modernaesthetics.com/news/call-for-entries-merz-aesthetics-announces-first-ever-innovation-forum/2473021/Merz Aesthetics is launching its first-ever Innovation Forum with a call for abstract submissions seeking the most creative and inventive medical aesthetics abstracts from the next generation of researchers and healthcare professionals. The author of the winning abstrac
- Promising Results from Dysport Dose Escalation Studyhttps://modernaesthetics.com/news/promising-results-from-dysport-dose-escalation-study/2473018/Top-line results from a Phase 2 dose escalation study show that significantly more subjects treated with Dysport® at all four doses achieved a composite two grade improvement responder rate than those treated with placebo at one month. The study accessed the duration of ef
- Soliton Appoints Aesthetic Executive Veteran Brad Hauser as President and CEO in Preparation for Commercial Launchhttps://modernaesthetics.com/news/soliton-appoints-aesthetic-executive-veteran-brad-hauser-as-president-and-ceo-in-preparation-for-commercial-launch/2473013/Soliton, Inc., has named Brad A. Hauser as President and Chief Executive Officer of Soliton. He most recently served as Vice President, R&D and General Manager for CoolSculpting at Allergan Aesthetics, an AbbVie Company, since Allergan's